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A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm
Initially Mimicking Cutaneous Lupus Erythematosus
Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare
hematologic malignancy that typically involves the skin, lymph
nodes, the peripheral blood and the bone marrow. This tumor
expresses CD4 and CD56 with no obvious evidence of B- or T-cell
differentiation. Since Adachi et al. (1) first described CD4+/CD56+
hematodermic neoplasm in 1994, several individual cases or small
groups of cases of this disease have been reported. The prognosis of
BPDCN is known to be extremely poor. Relapse frequently occurs
within 6 months or less from the initiation of chemotherapy and most
patients experience rapid progression that is refractory to conven-
tional chemotherapy. We report here on a case of advanced BPDCN
that was initially misdiagnosed as cutaneous lupus erythematosus. 
Case Report
A 67-year-old man with a past history of gout had complaints of
non-itching painless skin lesion on the back and it was spreading to
the whole trunk, face, arms and thighs for the previous 3 months.
This lesion initially presented as a dusky erythematosus patch with
indurations on the dorsal area, and it eventually grew and spread.
Skin examination showed multiple hyperemic nodules and plaques
on the face and trunk (Fig. 1). The antinuclear antibody was
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Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease. The prognosis is
poor in most cases with rapid progression despite administering chemotherapy. A 67-year-
old man complained of skin rashes on his back and this spread to the trunk, face, arms and
thighs, and he was initially diagnosed with cutaneous lupus erythematosus according to the
skin biopsy. The skin rashes then became aggravated on a trial of low dose methyl-
prednisolone for 3 months. Repeated skin biopsy revealed a diffuse infiltration of lymphoid
cells with medium sized nuclei, positive for CD4 and CD56, negative for Epstein-Barr virus
(EBV), indicating a diagnosis of BPDCN. Further workups confirmed stage IVA BPDCN in-
volving the skin, multiple lymph nodes, the peripheral blood and the bone marrow. He was
treated with six cycles of combination chemotherapy consisting of ifosphamide, me-
thotrexate, etoposide, prednisolone and L-asparaginase, and he achieved a partial response.
Herein we report on a rare case of BPDCN that was initially misinterpreted as cutaneous
lupus erythematosus. 
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│ http://www.e-crt.org│negative. A biopsy specimen taken from the facial skin lesion re-
vealed atrophy of the epidermis, a flattened stratum malpighii, small
numbers of necrotic keratinocytes and eosinophilic swelling of the
dermal collagen fibers, as well as a perivascular and interstitial
lymphohistiocytic infiltration in the entire dermis (Fig. 2). On the
basis of positive imunophenotyping for CD3 and CD20, the ne-
gative imunophenotyping for CD56 and the presence of a mixed
reactive lymphocytic infiltration of T and B-cells, a diagnosis of
lupus erythematosus was made. A trial of systemic steroid for 3
months improved his rashes. 
His rashes developed again on his face and anterior/posterior
trunk. Splenomegaly was detected without palpable lymph nodes.
The hemoglobin value was 12.2 g/dL, the platelet count was 83,000/
μ L and the white blood cell count was 22,900/μ L with 3% atypical
lymphocytes and 7% blasts. The serum levels of lactate dehydro-
genase, uric acid and creatinine were increased (1,580 IU/L, 10.5
mg/dL and 1.56 mg/dL, respectively). The marrow biopsy revealed
hypercellularity (70%) with diffuse tumor cell infiltration. Marrow
aspiration disclosed that blasts comprised 89% of the mononuclear
cells and the blasts were of variable size with agranular cytoplasm,
and they were positive for CD2, CD3, CD4, CD5, CD7, CD45,
CD56, and HLA-DR, and they were negative for myeloperoxidase,
terminal deoxynucleotidyl transferase, CD3, CD8, CD10, CD13,
CD14, CD19, CD20, CD33, CD34, and CD61. The blood coagula-
tion tests and urine analysis were unremarkable. Cytogenetic analy-
sis revealed a karyotype of 46, XY, add(9)(p24), del(11)(q22). 
Repeated biopsy from the left cheek revealed a diffuse lymphoid
infiltrate of cells with medium sized nuclei, and the cells were posi-
tive for CD4, CD43, CD56 and CD99 (Fig. 3), and this finding was
compatible with the diagnosis of BPDCN. Immunostaining for
CD3, CD6, CD8, CD20, CD30, T-cell intracellular antigen-1,
myeloperoxidase, and terminal deoxynucleotidyl transferase was
either weak or negative (Fig. 3). Epstein-Barr virus (EBV) was not
detected by RNA in situ hybridization, nor were EBV antibodies
detected. A study of T cell receptor gene rearrangement was not
performed because the patient did not give informed consent.
Computed tomography of the chest and abdomen showed multiple
lymphadenopathies in both axillae, the lower neck, the right lower
paratracheal area, the lower anterior mediatsinum, the left gastric
area, the pericholedocal site and the celiac axis area. 
The patient received six courses of multidrug chemotherapy
consisting of ifosphamide, methotrexed, etoposide, prednisolone
and L-asparaginase, and the patient achieved a partial remission. 
Discussion
BPDCN is a rare hematopoietic malignancy, and there has been
few data about its incidences. Spanish study (2) reporting the overall
incidence of BPDCN among all acute myeloid leukaemia and non-
Hodgkin’s lymphoma was 0.76% and 0.27%, respectively and
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Fig. 2. Findings of the initial skin biopsy. It shows scattered karyorrhectic
debris and eosinophilic swelling of the dermal collagen fibers with a
lymphocytic infiltration (×200).
A B
Fig. 1. Multiple nodules and plaques on
the (A) cheek and (B) trunk.Japanese study (3) reporting a 6.33% incidence of this malignancy
among natural killer (NK) cell-lineage neoplasm. In Korea, a total of
17 cases of BPDCN have been reported as single cases or as clusters
of cases. Among these cases, 4 cases (4) were reported in 2005 and
10 new cases (5) were reported in 2007, and all of these patients
died except for three patients who had disease confined to skin.
Since this disease entity was first described (1) in 1994, the no-
menclature has changed several times according to the expanded
knowledge of this malignancy. The naming of blastic NK cell
lymphoma/leukemia was based on the distinct cytology and NK cell
origin suggested by the CD56 expression. However, the CD4
positivity and the lack of expressing other NK-lineage markers in
most cases cast doubt on its derivation from NK precursors, and
hence the French Study Group on Cutaneous Lymphoma (6) called
it agranular CD4+/CD56+ hematodermic neoplasm. The World
Health Organization-European Organization for Research and Treat-
ment of Cancer (WHO-EORTC) consensus classification agreed (7)
because of the disease’s uncertain lineage. On further study, Chaperot
et al. (8) proposed that the plasmacytoid dendritic cell (PDC) might
be the normal counterpart of this disease in 2001. On the studies
using functional, immunohistochemical and molecular tools, the ex-
pressions of the interleukin 3 receptor α -subunit and blood dendritic
cell antigen-2 were compatible with a plasmacytoid dendritic cell
origin, and the authors of those studies named the disease BPDCN
(9). The name BPDCN was enlisted in the 2008 WHO classification
of tumors of the hematopoietic and lymphoid tissues. Although the
origin of this malady has been defined, the oncogenesis at the mo-
lecular level has yet to be clarified.  
Histopathologically, BPDCN is characterized by a dense
monomorphous infiltration of medium-sized blastoid cells that are
positive for CD4, CD56, CD123 and TCL-1. Cota et al. (10) evalu-
ated 33 patients with a proven diagnosis of BPDCN and they found
that the cutaneous lesions of BPDCN were quite variable. Most of
their cases (80%) presented with nodular/diffuse infiltrates in the
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Fig. 3. Findings of the second skin biopsy. (A) Shows an extensive diffuse infiltration of lymphoid cells (H&E, ×40). (B) Shows medium to
large size lymphoid cells with nuclear atypia (H&E, ×200). (C) Shows the positive staining for CD4 and (D) shows the positive stain for CD56
on immunohistochemistry (×100).Cancer Res Treat. 2010;42(4):239-243
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entire dermis, fewer cases (20%) presented with relatively small, pe-
rivascular or interstitial aggregates of cells, and some cases resem-
bled the picture of a cutaneous inflammatory disorder. The tumor
cells in the latter cases were found with reactive lymphocytes, and
this made the diagnosis of BPDCN difficult and dicey. In our case,
the skin lesion at first biopsy was suggestive of reactive change
rather than malignancy. The second biopsy revealed an extensive
diffuse lymphocytic infiltration that was positive for CD4, CD43,
CD56 and CD99, which is quite a different finding from the first
one and it definitely favored the diagnosis of BPDCN. This is cer-
tainly a lesson that both clinicians and pathologists should be aware
of the atypical presentations of BPDCN from the onset.
Lupus erythematosus is a chronic, inflammatory, autoimmune
disease. The histopathologic findings of discoid lupus erythema-
tosus are typified by an interface dermatitis involving the hair fol-
licles and epidermis, and this is accompanied by a moderate to
heavy superficial, deep perivascular and periappendageal lympho-
cytic infiltration. Plasmatoid dendritic cells are known to play an im-
portant role (11,12) in the pathogenesis of lupus erythematosus and
these cells produce type I interferon. Vermi et al. (13) showed that a
cutaneous plasmatoid dendritic cell infiltration is a hallmark of lupus
erythematosus. Although it is thought that BPDCN originates from
PDCs, there has been no report of BPDCN in the setting of lupus.  
BPDCN mainly occurs in older patients, although it can occur at
any age, including the pediatric period. It affects males more fre-
quently than females (12) at a proportion of roughly 3:1. It fre-
quently involves multiple sites with a predilection for skin, and this
is followed by bone marrow, peripheral blood and lymph nodes.
The skin lesions tend to be localized at the onset and then they
become multiple or more generalized during the course of disease,
and overt leukemia is the usual finding in advanced cases or there is
relapse after therapy. Rare cases involve the central nervous system
at presentation.
Frequent chromosomal aberrations in various sites have been
reported for this disease, including chromosomal losses on 5q, 6q,
12p, 13q and chromosomes 9 and 15, as well as deletion of regions
on 4q34, 9p13-p11, pq12-q34 and 13q12-q31. The significance of
these chromosomal abnormalities is not yet certain. Our case de-
monstrated an abnormal karyotype of 46, XY, add(9)(p24), del
(11)(q22). The comparative genomic hybridization performed in the
4 cases reported in Korea (5) showed amplification of 11q12.31 in
all 4 cases and 12q13.11 in three. 
The clinical course of BPDCN is aggressive and generally dire at
best, with the median survival time being 12-24 months. Although
there is no consensus on the optimal treatment for this neoplasm, a
systemic treatment should be started at the outset regardless of
whether the disease is localized or disseminated. Several reports
described a better prognosis for cases with skin involvement alone.
The clinical course in most cases has been characterized by an initial
response to chemotherapy followed by relapse and subsequent
death. As the outcomes of many therapeutic attempts have been
reported to be quite variable, there is no standard treatment for
BPDCN. Usually the duration of a response to topical steroid, single
agent chemotherapy, radiotherapy and polychemotherapy like
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or
HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexa-
methasone alternating with high dose methotrexate and high dose
cytarabine) has been reported to be brief. Pralatrexate was anecdo-
tally reported to be active as a salvage treatment (14) although its
impact on the clinical course looked negligible. In the face of the ex-
tremely poor outcome of conventional chemotherapy and radiation
therapy, Dalle et al. (15) asserted that only stem cell transplantation
can significantly prolong survival regardless of the initial extent of
disease. They claimed that stem cell transplantation should be
recommended for every eligible patient. Although our patient has
shown a partial response to six cycle of chemotherapy, his ultimate
prognosis looks grim.
Our case taught us a lesson that BPDCN should be considered in
the differential diagnosis of skin rashes that are refractory to treat-
ment. Although we could not identify PDCs in skin on the first biopsy
in our case, their accumulation has been described in several inflam-
matory cutaneous conditions (12) such as systemic lupus erythe-
matosus, psoriasis, lichen planus and contact dermatitis. Given its
easy accessibility and relative safety, we advocate that repeated skin
biopsy should be performed in every case of unusual skin lesion. Hye Jung Chang, et al_A Case of BPDCN That Mimicked Cutaneous LE
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